NASDAQ · Biotechnology · USD

Vogenx, Inc. (VOGX) Stock Analysis

Vogenx, Inc. (VOGX) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

VOGX

$20.39

+$1.64 (+8.75%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare VOGX with… →

VOGX Key Statistics

As of Oct 21, 2026

Trading

Open: $19.92
Previous Close: $18.75
Day's Range: 18.98–22.24
52-Week Range: 12.95–38.41
Volume: 84.31K

Valuation

Market Cap: $302.90M
P/E Ratio: unprofitable
EPS (ttm): −0.22

Financials (FY)

Revenue (FY): $0.00
Net Income (FY): −$1.45M
Shares Outstanding: 14.86M

Dividend and dates

Avg Volume: 173.08K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

Vogenx, Inc. (VOGX) has a market capitalization of $302.90M.

In fiscal 2025, VOGX reported revenue of $0.00.

VOGX Revenue and Earnings by Fiscal Year

FY ends December

Fiscal year	Revenue	Net income	Net margin
2025	$0.00	−$1.45M	—
2024	$0.00	−$2.20M	—

Fiscal year	Revenue	Gross profit	Operating income	Net income	Net margin
2025	$0.00	—	−$1.44M	−$1.45M	—
2024	$0.00	—	−$2.30M	−$2.20M	—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Vogenx, Inc. (VOGX) at $302.90M. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 4 employees.

Over the past 52 weeks the price has ranged from $12.95 to $38.41. VOGX last closed at $20.39 on October 21, 2026. That is +$1.64 (+8.75%) against the previous close. The latest close sits 57.45% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $0.00. The same year closed with a net loss of $1.45M. Earnings per share on a trailing basis come to −0.22.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published.

Growth & Income

No dividend is on file for VOGX.

So far in 2026 the total return is +56.85%.

Peer Comparison

Vogenx, Inc. (VOGX) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company	Ticker	Market Cap	P/E Ratio
Vogenx, Inc.	VOGX	$302.90M	—
Vertex Pharmaceuticals Incorporated	VRTX	$132.95B	30.4
Moderna, Inc.	MRNA	$98.14B	—
Regeneron Pharmaceuticals, Inc.	REGN	$82.95B	19.9

The Biotechnology industry average P/E ratio is 16.6x. Vogenx, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

MRNA

Moderna, Inc.

$98.14B

REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

ARGX

argenx SE

$55.97B

ONC

BeOne Medicines AG

$43.97B

RVMD

Revolution Medicines, Inc.

$41.64B

View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

JNJ

Johnson & Johnson

$621.22B

ABBV

AbbVie Inc.

$503.27B

UNH

UnitedHealth Group Incorporated

$374.30B

MRK

Merck & Co., Inc.

$369.78B

View all Healthcare stocks →

About Vogenx, Inc.

Vogenx, Inc. operates as a clinical-stage drug development company that develops therapeutics for metabolic including post-bariatric hypoglycemia, or PBH, and gastroparesis. Its products include drugs, such as Mizagliflozin and VGX-2857. It also offers VGX-001, a human monoclonal antibody for the treatment of type 1 diabetes (T1D). It caters to healthcare providers, physicians and third-party payors in the United States. The company was incorporated in 2021 and is based in Raleigh, North Carolina.

Visit website →